Healthcare & Life Sciences

Pain Neuroscience Education Versus Kinesio Tape for Carpal Tunnel Syndrome

Pain Neuroscience Education Versus Kinesio Tape for Carpal Tunnel Syndrome

ANS02 Phase 1 Study for EGFR NSCLC

ANS02 Phase 1 Study for EGFR NSCLC

Coffee Consumption Effects on Balance, University Students

Coffee Consumption Effects on Balance, University Students

Randomized Controlled Study on Mandala Coloring for Quality of Life in Epilepsy

Randomized Controlled Study on Mandala Coloring for Quality of Life in Epilepsy

Fuchs Dystrophy Descemet Polishing Clinical Trial NCT07539012

The NIH ClinicalTrials.gov registry has posted a new clinical trial (NCT07539012) titled 'Effect of Descemet Membrane Polishing in Fuchs Endothelial Corneal Dystrophy.' The study will evaluate whether polishing the Descemet membrane prior to cultured endothelial cell injection improves guttae removal and cell adhesion in Fuchs dystrophy patients. Corneal endothelial keratoplasty is currently the reference treatment, but graft shortages have driven interest in cell-based therapies.

Comparison of 7-Day vs 1-Day Packaging for SQ-LNS in Ethiopia

NIH ClinicalTrials.gov registered a mixed-methods field study (NCT07540793) comparing 7-day (7dp) vs 1-day (1dp) packaging of Small Quantity Lipid-based Nutrient Supplements (SQ-LNS) for children 6-24 months in North Shoa Zone, Amhara Region, Ethiopia. The study, conducted by Edesia Nutrition in partnership with Nutriset Développement, will evaluate acceptability and adherence to the new packaging design. The new 140g 7dp packet reduces cost by over 15% through 40% less packaging and 20% improved transportation efficiency.

Randomized Trial of Tranexamic Acid and Sucralfate for Gastrointestinal Tumor Bleeding

NIH registered Clinical Trial NCT07540026, a randomized controlled trial evaluating endoscopic application of tranexamic acid and sucralfate powders for hemostasis in gastrointestinal tumor bleeding. The study will recruit 60 patients at National Cheng Kung University Hospital in Taiwan, comparing active treatment (3g sucralfate powder and 1.5g tranexamic acid powder) against standard treatment. The trial is listed as ongoing with an estimated completion date of April 20, 2026.

Factors Affecting Immediate Anterior Implants: Retrospective Clinical Study

The NIH ClinicalTrials.gov registry has posted a retrospective cohort study (NCT07539168) evaluating clinical, surgical, and prosthetic factors associated with outcomes of immediate implant placement in the anterior maxilla. The observational study aims to identify predictors of implant survival and complications within 12 months of placement, and will assess peri-implant marginal bone loss, prosthetic complications, and esthetic outcomes using the pink esthetic score.

Biomarker Panel Forecasts Chronic GVHD After Allo-HSCT

NIH registered a single-center observational clinical study (NCT07539220) investigating a biomarker panel for forecasting chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The discovery cohort enrolled 1000 consecutive patients retrospectively from January 2021 to June 2023, while a validation cohort of 500 recipients was enrolled from June 2023 to June 2024. Heparinized blood samples were collected at day +90 post-HSCT and analyzed using multiplex mass spectrometry with pooled plasma to compare proteomic profiles between patients with and without cGVHD.

Telerehabilitation in Patients With Bronchiectasis

The NIH registered a new randomized controlled trial (NCT07539571) on ClinicalTrials.gov evaluating home-based telerehabilitation for patients with bronchiectasis. The single-center trial will be conducted at Virgen del Rocío University Hospital in Spain, randomizing participants to usual care or a 12-week supervised telerehabilitation program three times per week. Outcome measures include the 6-minute walk test, quality-of-life questionnaires, pulmonary function tests, and inflammatory biomarkers.

HBVCare Mobile App Chronic Hepatitis B Treatment Adherence Randomized Controlled Trial

NIH registered clinical trial NCT07540637, a multicenter randomized controlled trial evaluating the HBVCare mobile application for improving treatment adherence in chronic Hepatitis B patients at Hoang Long Clinic and Hanoi Medical University Hospital in Vietnam. Patients are randomized to standard care or HBVCare app intervention, with adherence outcomes assessed at three months.

Celsio Cryocatheter Disposable System Bronchoscopy Study

NIH registered a new clinical trial on ClinicalTrials.gov evaluating the Celsio Disposable Cryocatheter System for diagnostic and interventional bronchoscopy in patients with lung cancer and interstitial lung disease. The study aims to generate real-world evidence on device performance and identify best practices without interfering with standard clinical care.

Functionally Optimized CD33 CAR-T for AML, Phase 1 Trial NCT07538713

NIH registers Phase 1 trial NCT07538713 evaluating functionally optimized CD33 CAR-T (FO33 CAR-T) cell therapy in patients with recurrent/refractory acute myeloid leukemia (AML). The single-arm study will assess safety, tolerability, and preliminary efficacy of the CD33-targeted therapy. CD33 is expressed in leukemia cells from over 80% of AML patients and was selected as the target antigen due to higher expression levels across AML subtypes compared to alternative targets such as CLL-1 and CD123.

Investigation of Patients Presenting With Acute Functional Neurological Symptoms

NIH ClinicalTrials.gov registered NCT07538414, a retrospective single-center observational study analyzing patients presenting with acute functional neurological symptoms. The study aims to characterize the frequency, clinical features, diagnostic pathways, and healthcare utilization of patients with functional neurological disorder. Data collection is limited to retrospective patient data review; no prospective interventions are involved.

Technical Review Panel Public Meeting Notice

Indiana Department of Health has posted a public meeting notice for the Technical Review Panel. The meeting is scheduled for Friday, March 27, 2026, at 10 a.m. EST in the Robert O. Yoho Board Room at 2 N. Meridian St., Indianapolis, IN 46204. Virtual attendance options via Microsoft Teams and telephone are available.

Hospital Violence Intervention Program (HVIP+) Community Model, Central Arkansas

The National Institutes of Health has registered a new clinical trial (NCT07539142) testing the preliminary efficacy of a Hospital-based Violence Intervention Program (HVIP) in Central Arkansas. The optimization randomized control trial will evaluate interventions including Brief Bedside, Peer Support, Case Management with Voucher, and SELF Group Therapy Sessions for hospital-based violence intervention, community firearm violence, and firearm behaviors.

Observational Safety Trial of CT0494BCP in Advanced Gastric/Esophagogastric Junction Adenocarcinoma

A new observational safety trial (NCT07538856) evaluating CT0494BCP cell therapy in participants with advanced gastric/esophagogastric junction adenocarcinoma has been registered on ClinicalTrials.gov. The study uses Bayesian optimal interval (BOIN) design for dose escalation across six dose groups. CT0494 cells are assigned to three escalating doses (3.0×10⁸, 4.5×10⁸, 6.0×10⁸), and CT7095 cells to two escalating doses (1.5×10⁸, 3.0×10⁸). The trial will assess safety, tolerability, preliminary efficacy, and cellular metabolism kinetics.

Effectiveness of Ambulatory Transcutaneous Tibial Nerve Stimulation for Overactive Bladder

NIH has registered a randomized clinical trial (NCT07540273) comparing ambulatory versus clinic-based transcutaneous tibial nerve stimulation for treating overactive bladder in adults aged 18-65. The two-arm study will enroll participants receiving identical electrical stimulation parameters (20 Hz, 200 µs) delivered either at home via portable device or in-clinic twice weekly over 2 weeks. The trial will assess urgency episode frequency, bladder symptoms, and quality of life outcomes.

WECARE Study, Chinese American Dementia Caregivers

NIH has registered a new clinical trial, NCT07539350, titled 'WECARE Study,' testing a seven-week multimedia wellness intervention for Chinese American family caregivers of persons with Alzheimer's disease and related dementias. The trial aims to determine whether the WECARE program improves caregiver well-being and reduces stress related to caregiving for persons with caregiver burden. The study does not create compliance obligations for regulated entities.

Effect of Internal Jugular Vein Catheterization on Intracranial Pressure and Intracranial Blood Flow

The National Institutes of Health registered a prospective observational clinical study (NCT07540481) evaluating the effect of internal jugular vein catheterization on intracranial pressure using optic nerve sheath diameter measurements and carotid artery Doppler ultrasonography in adult patients undergoing surgery under general anesthesia. The study will assess ONSD changes at two time points and secondary Doppler parameters. No compliance obligations or deadlines are imposed by this registration.

Pilot RCT Tests ACT for Perinatal Loss Mental Health

NIH registered a pilot randomized controlled trial (NCT07538011) evaluating an Acceptance and Commitment Therapy-based psychosocial intervention for women who have experienced perinatal loss. The 4-week mixed-format program includes four in-person sessions and two videoconferencing sessions, with a 30-minute booster one month post-completion. The study will assess feasibility, acceptability, and preliminary effects on perinatal grief, PTSD, depression, anxiety, psychological flexibility, and social support.

Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS)

NIH ClinicalTrials.gov has registered a single-arm, open-label Phase I exploratory study (NCT07538479) evaluating controlled cold exposure combined with standard PD-1/PD-L1 inhibitor-based therapy in 24 participants with solid malignancies. The primary objectives are to evaluate safety, tolerability, and feasibility of the cold exposure intervention. Secondary objectives include exploring preliminary antitumor activity and effects on brown adipose tissue activation, peripheral immune profiling, circulating cytokines, metabolomics, gut microbiota, and tumor biomarkers.

HDM2024 Phase 1 Trial, Advanced Solid Tumors

NIH registered a Phase 1 clinical trial (NCT07539285) for HDM2024, an investigational drug, in participants with advanced solid tumors. The trial will evaluate drug safety, tolerability, and antitumor activity. Participants receive the study drug once every three weeks, with imaging-based efficacy assessments every six weeks.

Bambini Kids Robot-Assisted Gait Training Safety and Effectiveness Trial in Children With Cerebral Palsy

NIH has registered a clinical trial evaluating the safety and effectiveness of the Bambini Kids pediatric robotic exoskeleton in children with cerebral palsy (CP). The single-arm study will assess robot-assisted gait training (RAGT) as an intervention for gait impairment and motor performance limitations in the pediatric CP population. The trial is registered as NCT07539389 with an estimated completion date of April 20, 2026.

Ultrasound-Guided Percutaneous Needle Tenotomy vs Percutaneous Ultrasonic Needle Tenotomy for Gluteal Tendinosis

NIH ClinicalTrials.gov registered a new clinical study (NCT07540806) comparing two tenotomy techniques for gluteal tendinosis: standard percutaneous needle tenotomy (PNT) versus percutaneous ultrasonic tenotomy (PUT) using the Tenex device. The study's primary endpoints are pain improvement and functional outcomes. This is an informational database entry; no regulatory obligations or compliance requirements are created.

Youth Cannabis Use Continued to Decline in 2025

The Minnesota Department of Health released findings from the 2025 Minnesota Student Survey showing 96% of students reported not using cannabis in the last month, and a 57.7% decrease in past 12-month use among eighth, ninth, and 11th graders since 2013. The survey, conducted between January and June 2025, is Minnesota's first since adult cannabis use was legalized in 2023.

AI-Guided Atrial Fibrillation Detection After Ischemic Stroke: Prospective Randomized Trial

NIH registered a prospective randomized trial (NCT07540065) comparing AI-guided atrial fibrillation risk stratification plus intensified rhythm monitoring (wearable devices, extended ECG patches) against standard care in post-ischemic stroke patients. The trial enrolls an Active Follow-up Group and a Standard Follow-up Group, with conditions including Atrial Fibrillation, Stroke, and Artificial Intelligence. The primary hypothesis is that AI-assisted ECG analysis will significantly increase AF detection rates and enable earlier anticoagulation decisions while reducing unnecessary bleeding risk exposure.

VALsartan on atRIAl Mitral Regurgitation Pilot Randomized Controlled Trial Phase 2

NIH ClinicalTrials.gov registered a Phase 2 pilot randomized controlled trial (NCT07539298) evaluating valsartan versus placebo for treatment of atrial functional mitral regurgitation in adults with preserved left ventricular ejection fraction. The 12-month study will assess progression reduction, mitral valve leaflet remodeling, and safety/tolerability. Participants will undergo 3D echocardiography, 6-minute walk tests, and Kansas City Cardiomyopathy Questionnaire assessments.

BPS-Tech Pilot Trial for Eighth Graders

NIH has registered a pilot clinical trial (NCT07540819) testing a single-session writing exercise called Best Possible Self-Tech (BPS-Tech) with eighth graders. The study aims to assess feasibility and acceptability of classroom delivery, and to examine associations between textual features and positive affect outcomes.

Observational TFESI Efficacy in Lumbar Radicular Pain

NIH registered an observational study (NCT07538765) evaluating the effectiveness of transforaminal epidural steroid injections (TFESI) in patients aged 18 to 90 with radicular low back pain caused by lumbar disc herniation who did not improve with conservative treatment. The three-month study tracks pain reduction using the Visual Analog Scale and functional improvement using the Oswestry Disability Index. No compliance obligations or deadlines are created by this registry entry.

Virtual Intervention for Behavioral Health in Emerging Adults; VIBE in the Parks

NIH ClinicalTrials.gov has registered a randomized clinical trial (NCT07539636) evaluating a digital behavioral health intervention, 'VIBE in the Parks', for adolescents and young adults experiencing anxiety and depression. The study will be conducted at four Chicago Park District sites, comparing the digital treatment to a control condition using a digital workbook.

QI-019B Phase 1 Trial for Relapsed/Refractory Multiple Myeloma

NIH registered Phase 1 trial NCT07539233 evaluating QI-019B Injection in patients with relapsed/refractory multiple myeloma. The single-arm, open-label, single-center study will assess safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the investigational drug.

Optimizing Early Nutrition Management of Extremely and/or Very Preterm Infants

NIH ClinicalTrials.gov has registered a clinical quality improvement study (NCT07538999) evaluating an early nutrition management bundle for extremely and/or very preterm infants. The bundle combines three interventions: individualized human milk feeding, early enteral zinc supplementation, and routine parenteral carnitine supplementation. The study will assess clinical outcomes including growth, organ function, and neurodevelopment compared to routine nutritional strategies.

Phase 2 Emapalumab Trial for Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft Dysfunction

The NIH has registered a Phase 2 clinical trial on ClinicalTrials.gov testing emapalumab versus placebo in lung transplant recipients experiencing acute lung allograft dysfunction (ALAD), a serious complication with no approved treatment. The trial (NCT07538336) plans to enroll approximately 90 participants with a primary completion date of April 20, 2026. This is a routine trial registration providing public access to study parameters and eligibility criteria.

Phase I CY-219 CAR-T Cell Injection for Relapsed/Refractory B-Cell Lymphoma

The National Institutes of Health registered a Phase I clinical study (NCT07539688) evaluating the safety and efficacy of CY-219 CAR-T cell injection in patients with relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma and transformed indolent B-cell lymphoma. The open-label, single-arm trial is sponsored by Changebridge Pharmaceutical Co., Ltd. and enrolls patients meeting specific disease criteria.

NY OMH Opens 24/7 Crisis Stabilization Center in Brooklyn

NY OMH announced the opening of a new 24/7 Supportive Crisis Stabilization Center operated by Services for the UnderServed at 2862 Fulton St. in East New York, Brooklyn. The facility, licensed in partnership with OASAS, provides voluntary, short-term behavioral health stabilization services for up to 24 hours as an alternative to unnecessary emergency room visits. The center received $1.2 million in start-up funding and $4.5 million in operating funding over five years.

34-Unit Schenectady Specialized Mental Health Housing Groundbreaking

Governor Hochul announced the groundbreaking for Mohawk Heights, a 34-unit specialized housing development in Schenectady for adults living with mental illness who are homeless or at risk. The project is funded by $15.6 million from the Office of Mental Health plus approximately $750,000 in annual operating funds, with construction financing from DASNY. The 11,459-square-foot building is expected to open in Q1 2027.

New Crisis Stabilization Center Opens in Utica

The New York State Office of Mental Health announced the opening of a new Supportive Crisis Stabilization Center in Utica, operated by Upstate Caring Partners. The facility, located at 1002 Oswego Street, provides 24/7 behavioral health crisis services including immediate stabilization and therapeutic support for individuals experiencing mental health or substance use challenges. The center was awarded $3.8 million over five years and is licensed in partnership with the Office of Addiction Services and Supports.

Program Memos

The CA Department of Aging Licensing publishes a landing page providing access to program memos and policy updates for aging services programs in California. No specific regulatory content, memos, or policy changes are provided in this listing — the page serves as a navigation portal with a subscription link for receiving future communications.

Bridge to Recovery $55.84M Grant Round 2 Closed

The California Department of Aging (CDA) announces that Round 2 of the Bridge to Recovery grant program is now closed. The $55.84 million program supports in-center congregate services for at-risk older adults and people with disabilities, providing funding to day-service providers for infection prevention and workforce shortage mitigation.

Regulatory Updates and Policy Documents Portal

The California Department of Aging provides public access to its regulatory actions including proposed and approved regulations under the Older Americans Act and California Welfare and Institutions Code. Current proposals include three regular rulemaking items covering quarterly reviews, definition of local government units, and revocation of Area Agency on Aging designations. The page outlines the public comment process and hearing procedures in compliance with California Government Code section 11346.5.

Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL

NIH ClinicalTrials.gov registered a Phase 2 clinical trial (NCT07538180) evaluating a three-stage treatment protocol for newly diagnosed elderly patients with MYC/BCL2 double-expressor DLBCL. The protocol consists of chemotherapy-free SCR therapy (Serplulimab, Chidamide, Rituximab), followed by R-CHOP chemotherapy, then maintenance therapy. The trial enrolls elderly patients and allows R-miniCHOP for frail patients over 75 years.

Observational Case Series of Futsal Goalkeeper Barrier-Step Movement

NIH ClinicalTrials.gov registered observational study NCT07539246 examining barrier-step movement in three elite male futsal goalkeepers. The study used high-speed video analysis to characterize movement phases and body angles during standardized low ball stimulus responses. No compliance obligations or regulatory requirements are created by this registration.

QIPB in Hip Surgery - Opioid Consumption Measurement Study

This single-center retrospective study registered on ClinicalTrials.gov examines patients who underwent hip surgery between May 2025 and November 2025. The study compares patients receiving Quadro Iliac Plane Block (QIPB) plus patient-controlled analgesia against a control group using only patient-controlled analgesia. Primary endpoint is total opioid consumption over 24 hours, with secondary endpoints including pain scores and rescue analgesia requirements.

MInimizing Delirium With Nasal Dexmedetomidine-InducEd Sleep (MIDDIES)

NIH registered a Phase 2 clinical trial (NCT07538284) titled MIDDIES on ClinicalTrials.gov. The trial will study whether nighttime self-administration of nasal dexmedetomidine is effective at inducing sleep and preventing postoperative delirium in high-risk patients undergoing major abdominal surgery, compared with placebo.

Phase 3 RCT of GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced Nasopharyngeal Carcinoma

NIH registered a Phase 3 randomized controlled clinical trial (NCT07540390) evaluating GAPP induction therapy combined with concurrent chemoradiotherapy and toripalimab maintenance for high-risk locoregionally advanced nasopharyngeal carcinoma (Stage III, AJCC 9th edition). The experimental arm combines PD-1 antibody (toripalimab), anlotinib, cisplatin, gemcitabine, and radiation, while the control arm uses the current guideline-recommended GPP induction chemotherapy regimen. The multicenter open-label study aims to generate evidence-based data on the efficacy and safety of this novel combination.

Oral Probiotics vs Placebo Pakistani Moderate Acne Study

ClinicalTrials.gov registered a randomized controlled trial (NCT07539129) evaluating oral probiotics versus placebo in 64 Pakistani patients with moderate Acne Vulgaris over 12 weeks. The primary endpoint is reduction in total acne lesion count; secondary endpoint is change in serum Interleukin-6 levels. The study will use GAGS scoring and standardized photography for clinical assessment.

Study Compares Caries Removal Methods, Oral Microbiome Effects

The National Institutes of Health registered a clinical study on ClinicalTrials.gov (NCT07538089) evaluating how selective and non-selective caries removal methods affect oral microbiome composition using 16S rRNA gene sequencing. The study targets dental caries patients and will assess microbial diversity outcomes from two intervention approaches.

Suzetrigine Phase 3 Trial for Cardiac and Bariatric Surgery Patients NCT07539623

NIH registered Phase 3 clinical trial NCT07539623 on ClinicalTrials.gov, evaluating Suzetrigine as an addition to multimodal pain regimens for post-operative pain management in bariatric and cardiac surgery patients. The prospective, randomized study will assess whether Suzetrigine reduces opioid consumption and pain scores compared to placebo in participants undergoing weight-loss surgery or sternotomy.

Phase 2 Dapagliflozin Spironolactone Aortic Valve Replacement Trial

NIH registered a Phase 2 randomized controlled trial (NCT07539259) evaluating dapagliflozin and spironolactone in patients with severe aortic stenosis undergoing aortic valve replacement. The four-arm trial will assess whether these heart failure medications improve left ventricular mass regression, myocardial health, and patient-reported outcomes compared to standard-of-care alone over 12 months.